FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/10/075580 [Registered on: 21/10/2024] Trial Registered Prospectively
Last Modified On: 15/10/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Single Arm Study 
Public Title of Study   Assessing the combined efficacy of Ruksha Churna Pinda Sweda, Virechana, and Kshara Basti (Yoga Basti) in managing Amavata (Ankylosing Spondylitis): An Open-Label Clinical Study 
Scientific Title of Study   Evaluation of the combined efficacy of Ruksha Churna Pinda Sweda ,Virechana and Kshara Basti(Yoga Basti)in the management of Amavata(Ankylosing Spondylitis):Single Arm Open Ended Clinical Study 
Trial Acronym  nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Prem Lata 
Designation  PG Scholar 
Affiliation  All India Institute Of Ayurveda 
Address  OPD 6, Department of Panchakarma, All India Institute of Ayurveda, Gautampuri, Sarita Vihar Room no 725, Department of Panchakarma, Academic Block, All India Institute of Ayurveda, Delhi South

South
DELHI
110076
India 
Phone  8988406358  
Fax    
Email  premlatajan11@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Prasanth Dharmarajan 
Designation  Associate Professor 
Affiliation  All India Institute Of Ayurveda 
Address  Room No. 725, Department of Panchakarma Academic Block, All India Institute of Ayurveda Gautampuri, Sarita Vihar, Delhi South

South
DELHI
110076
India 
Phone  9895174060  
Fax    
Email  drprasanthd@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Prasanth Dharmarajan 
Designation  Associate Professor 
Affiliation  All India Institute Of Ayurveda 
Address  Room No. 725, Department of Panchakarma Academic Block, All India Institute of Ayurveda Gautampuri, Sarita Vihar, Delhi South

South
DELHI
110076
India 
Phone  9895174060  
Fax    
Email  drprasanthd@gmail.com  
 
Source of Monetary or Material Support  
All India Institute Of Ayurveda, Gautampuri Awas, Sarita Vihar ,Delhi South ,110076 New Delhi India  
 
Primary Sponsor  
Name  All India Institute Of Ayurveda 
Address  All India Institute Of Ayurveda ,Gautampuri,Sarita Vihar,Delhi-110076 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Prem Lata  All India Institute Of Ayurveda  OPD No.6,Department of Panchakarma,Gautampuri Awas, Sarita Vihar,Delhi South,110076 New Delhi India
South
DELHI 
8988406358

premlatajan11@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Division Of Translational Research And Biostatistics,All India Institute Of Ayurveda,Delhi south  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:M45||Ankylosing spondylitis. Ayurveda Condition: AMAVATAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmProcedure-Ruksha churna pinda sweda (Procedure Reference: Charak samhita sutra sthana chapter -14,verse-41, Procedure details: In forenoon for 30 minutes ,7days)
(1) Medicine Name: Kolakulathadi churna, Reference: Charak samhita sutra sthana chapter -3,verse-18, Route: Topical, Dosage Form: Churna/ Powder, Dose: 500(g), Frequency: od, Duration: 7 Days
2Intervention ArmDrugClassical(1) Medicine Name: Panchakola churna, Reference: Bhavaprakash -purva khanda-Haritakyadi verga, Route: Oral, Dosage Form: Churna/ Powder, Dose: 3(g), Frequency: bd, Bhaishajya Kal: Pragbhakta, Duration: 7 Days, anupAna/sahapAna: Yes(details: -ghee), Additional Information: -
3Intervention ArmProcedure-snehapAna-karma, स्नेहपान-कर्म (Procedure Reference: Charak samhita sutra sthana chapter-13, Procedure details: In early morning (6-8am),for 3-7 days)
(1) Medicine Name: Shatapala ghrita, Reference: Charak samhita chikitsa sthana chapter-6,verse-169, Route: Oral, Dosage Form: Ghrita, Dose: 500(ml), Frequency: od, Duration: 7 Days
4Intervention ArmProcedure-aBya~gga-karma, अभ्यंग-कर्म (Procedure Reference: Sushrut samhita chikitsa sthana chapter 24, Procedure details: In morning (10-11am) 3 days for 30 minutes)
(1) Medicine Name: Brihat saindhavadi taila, Reference: Bhaishajya ratnavali -amavata chikitsa prakaran, Route: Topical, Dosage Form: Taila, Dose: 150(ml), Frequency: od, Duration: 3 Days
5Intervention ArmProcedure-Saravanga vashpa sweda (Procedure Reference: Sushrut samhita chikitsa sthana chapter-32,verse-5-11, Procedure details: In morning (10-11am)3 days for 30 minutes)
(1) Medicine Name: Dashmool kwatha, Reference: bhaishajya ratnavali ,kasarogadhikar , Route: Topical, Dosage Form: Kwatha/Kashaya, Dose: 100(g), Frequency: od, Duration: 3 Days
6Intervention ArmProcedure-virecana-karma, विरेचन-कर्म (Procedure Reference: Charak samhita kalpa sthana chapter-1 ,verse-4, Procedure details: In morning(10-11am) for 1 day)
(1) Medicine Name: Trivrit avaleha, Reference: Ashtanghrudayam samhita kalpa sthana chapter -2 ,verse -9, Route: Oral, Dosage Form: Kalka/ Paste, Dose: 40(g), Frequency: od, Duration: 1 Days
(2) Medicine Name: Triphala kwatha, Reference: Bhavaprakash -Haritakyadi verga, Route: Oral, Dosage Form: Kwatha/Kashaya, Dose: 100(ml), Frequency: od, Duration: 1 Days
(3) Medicine Name: Ghandharvahastadi eranda taila, Reference: Ashtanga sangraha chikitsa sthana chapter-15, Route: Oral, Dosage Form: Taila, Dose: 30(ml), Frequency: od, Duration: 1 Days
7Intervention ArmProcedure-saMsarjana-kramaH, संसर्जन-क्रमः (Procedure Reference: charak samhita siddhi sthana chapter -6,verse-24, Procedure details: for 3-5 days ,according to shuddhi)
8Intervention ArmProcedure-anuvAsana-bastiH, अनुवासन-बस्तिः (Procedure Reference: Charak samhita siddhi sthana chapter-1,verse-29-34, Procedure details: on 1st ,3rd,5th,7th,8th day of yoga basti)
(1) Medicine Name: Brihat saindhavadi taila, Reference: Bhaishajya ratnavali -amavata chikitsa prakaran, Route: Rectal, Dosage Form: Taila, Dose: 80(ml), Frequency: od, Duration: 5 Days
9Intervention ArmProcedure-AsthApana-bastiH/ nirUha-bastiH, आस्थापन-बस्तिः/ निरूह-बस्तिः (Procedure Reference: Charak samhita siddhi sthana chapter-1,verse-27-28, Procedure details: On 2nd,4th,6th day of yoga basti, morning time (8-11am)in empty stomach)
(1) Medicine Name: kshara basti, Reference: Chakradatta samhita -niruha basti adhikaar , Route: Rectal, Dosage Form: Kwatha/Kashaya, Dose: 600(ml), Frequency: od, Duration: 3 Days
10Intervention ArmDrugClassical(1) Medicine Name: Trayodashang guggulu, Reference: Bhaishajya ratnavali -vatavyadhi rogadhikaar, Route: Oral, Dosage Form: Guggulu , Dose: 500(mg), Frequency: tds, Bhaishajya Kal: Adhobhakta, Duration: 30 Days, anupAna/sahapAna: No, Additional Information: -
11Intervention ArmDrugClassical(1) Medicine Name: Rasnasaptak kwatha, Reference: Chakradatta samhita-Amavata rogadhikaar, Route: Oral, Dosage Form: Kwatha/ Kashaya, Dose: 20(ml), Frequency: tds, Bhaishajya Kal: Abhakta, Duration: 30 Days, anupAna/sahapAna: No, Additional Information: -
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1. Age between 18 yrs. to 60 yrs
2. Chronicity: 1yr to 5 years.
3. Gender: Both
4. . Diagnosed cases of Ankylosing
Spondylitis.(upto Grade 2 of sacroiliitis).
5. Socio- economic status: All 
 
ExclusionCriteria 
Details  1. Chronicity of more than 5 yrs
2. Severely deformed joints.
3. Cardiac disease, pulmonary tuberculosis,
severe lung disease, diabetes and pregnant
women.
4. Patients unfit for Snehana, Svedana,
Virechana and Basti Karma.
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Reduction in pain and stiffness.  0th day,7th day,21th day,30th day,60th day,90th day 
 
Secondary Outcome  
Outcome  TimePoints 
1.Overall improvement in quality of life.
2. Reduction in inflammation and fatigue.
3.Measurement of changes in Inflammatory markers q-CRP,ESR,INTERLEUKIN-17.  
0th day ,90th day 
 
Target Sample Size   Total Sample Size="27"
Sample Size from India="27" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   01/03/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

RESEARCH QUESTION

 

What is the combined effect of Ruksha churna pinda sweda, Virechana and Kshara basti(Yoga  basti )followed by Trayodashanga guggulu and  Rasnasaptak kwatha in the management  of Amavata (Ankylosing spondylitis).

HYPOTHESIS

 Null hypothesis:(H0)

There is no significant effect of Ruksha churna pinda sveda, Virechana and Kshara basti(Yoga  basti) followed by Trayodashang guggulu and Rasnasaptak kwatha in the management  of Amavata ( Ankylosing spondylitis).

  Alternate hypothesis:(H1)

There is significant effect of Ruksha churna pinda sveda, Virechana and kshara basti( Yoga basti ) followed by Trayodashang guggulu and Rasnasaptak kwatha in the management of  Amavata ( Ankylosing  spondylitis).

NEED OF THE STUDY

·       The prevalence of AS is generally believed to be between 0.1% and 0.4% globally  while in India, around 0.25% population is estimated to be affected4. The disease is more  often manifest in young males than in females with the ratio approximately 3:15.

·       Ankylosing spondylitis is a chronic inflammatory condition marked by the formation of new bone in the axial skeleton. It leads to ongoing and irreversible structural deterioration of the spine, sacroiliac, and peripheral joints. Additionally, it may present with extra-articular symptoms like uveitis, psoriasis, inflammatory bowel disease, and cardiovascular and pulmonary abnormalities.

·       The initial treatment approach for ankylosing spondylitis typically involves nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). However, these medications often fall short in effectively managing disease symptoms. Biologic therapies, specifically anti-tumor necrosis factor (anti-TNF) agents, are currently approved for AS treatment and have demonstrated efficacy in achieving clinical remission for durations extending up to 8 years.

·       Unfortunately,there are some adverse effects associated with these drugs which can be considered mild or severe and these treatments are expensive and prognosis is very poor.

·       Unavailability of satisfactory treatment in bio-medicine leads to permanent deformity in Ankylosing spondylitis. There is a need to search satisfactory treatment available in other medical system. Hence there is a  need of cost effective treatment,which improve the Quality of Life in patients having no side effects.

·       The menifestation of Vata Vyadhi, a condition attributed to Vata dosha imbalance, becomes evident in fully developed ankylosing spondylitis (AS). As the disease advances, nearby articular or joint tissues undergo destruction, with original cartilage being replaced by bone through fusion. Consequently, joint bones fuse together, resulting in stiffness and reduced mobility. This fusion process ultimately leads to the characteristic "bamboo spine" formation, a hallmark of AS.

·        In Ayurveda ,Ankylosing spondylitis is not mentioned as a separate disease  in clasical texts, but considering the symptom and the cause, disease can be  approached with the concepts of vatavyadhi with special reference to Amavata.

·        The  main symptoms are shoola, graha that mainly occurs in kati,trika and prishtha desha which is  a dominant features of vata dosha.

·        Stambha /graha is could be seen when kaphavritt/amavritta vata prokopa develops6.

·       Pinda Sveda is describe in samhita in the context of svedana to allivate vata and kapha  dosha and ruksha churna pinda sveda  having the quality of ruksha guna with vatahara dravya  which is useful in kaphavritta vata7.

·       Deepan – Panchakola have Laghu, Ruksha ,and Sukshma Guna ,Ushna Virya,Katu Rasa,Katu vipaka and kaphahara and pachana properties . BY Katu Rasa and Vipaka Panchakola helpful in Agnideepana.

·        Virechana is a therapy which is indicated for Shodhana purpose. By virtue of it, the Doshas are eliminated by Adhomarga. After niram condition of vata ,the treatment of nirama vata should be snehana ,svedana and snigdha virechana.

·       Basti is considered as Ardhachikitsa and best measure to control vitiated Vata Dosha. Basti helps in the management of Amavata as Vata is  of the main causative factors.

·       Basti is very useful in chronic stage of Amavata.Both Anuvasana and Asthapana Basti are recommended in Amavata. Chakradutta has recommended Saindhavadi Taila Anuvasana Basti and Kshara Basti as Asthapana Basti in Amavata.

OBJECTIVES OF THE RESEARCH PROJECT

 

  PRIMARY:         To evaluate the combined effect of Ruksha churna pinda sweda, Virechana and Kshara basti(yoga Basti) followed by Trayodashang guggulu  and Rasnasaptak kwatha in  the  management of reducing pain  and stiffness in the Amavata. (Ankylosing spondylitis).

 

                      

 SECONDARY: 1) To reduce the other symptoms like inflammation, fatigue etc.

                             2) To improve the Quality of Life in patients of Ankylosing spondylitis.

                        3)To asses the inflammatory markers changes- qCRP,ESR,Interleukin-17

MATERIALS AND METHOD

STUDY TYPE: Interventional

STUDY  DESIGN: Single arm open ended  clinical study

SAMPLING METHOD: Non Randomisation

GROUPING: Single Arm

TIMING: Prospective

MASKING:open Label

ENDPOINT:Efficacy

SAMPLE SIZE- 27

SAMPLE SIZE CALCULATION

A study on Ankylosing spondylitis is proposed to evaluate the impact of What is the  combined effect of Ruksha churna pinda sweda, Virechana and Kshara basti(Yoga  basti) followed by Trayodashanga guggulu and Rasnasaptak kwatha in the management  of Amavata (Ankylosing spondylitis) on pain management beside other indicators.

 

A study done earlier suggest the mean is scored among such patients is around 6 with standard deviation of 2.

It may be assumed that VAS SCORE may be further reduce by 20 % from a mean level of 6 to 4.8% after the intervention.

 

In sample size calculation following parameter are used-

 Level of significance is 5% and power of the test is 80% two sided test and effect size of 0.60% gives a calculated sample size of 24.

Adjusting this for10% drop out study would include 27 patients.


CRITERIA FOR SELECTION

         Patients are collected from OPD (AIIA) in the basis of Ankylosing diagnostic criteria.

INCLUSION CRITERIA 

 

EXCLUSION CRITERIA

1. Age between 18 yrs. to 60 yrs.

 

1. Chronicity of more than 5 yrs.

 

2. Chronicity: 1yr to 5 years. 

 

2. Severely deformed joints.

3. Gender: Both

3. Cardiac disease, pulmonary tuberculosis, severe lung disease, diabetes and pregnant women.

 

4. . Diagnosed cases of Ankylosing

Spondylitis.(upto Grade 2 of sacroiliitis)

 

4. Patients unfit for Snehana, Svedana,  Virechana and Basti Karma.

 

 

5. Socio- economic status: All

                    

 

CRITERIA  FOR  DIAGNOSIS :    The Assessment of Spondylo Arthritis international Society (ASAS) criteria for Ankylosing Spondylitis11.

(ICD-11 code-FA92.0 axial spondyloarthrits)

ASAS classification criteria for axial Spondylo Arthritis are as follows-

•        Back pain for 3 months or longer

•        Age at onset < 45 years

•        Sacroillitis on imaging (radiographs or MRI) plus one or more Spondylo Arthritis features 

•        HLA-B27 plus two or more other Spondylo Arthritis features

 

Spondylo Arthritis features are as follows:

•        Inflammatory back pain

•        Arthritis

•        Enthesitis 

•        Uveitis

•        Dactylitis

•        Psoriasis

•        Crohn disease

•        Good response to NSAIDs

•        Family history of SpA

•        HLA-B27s

•        Elevated ESR


Total no. of. Days treatment given

•       Ruksha churna pinda sveda with Kolakullathadi choorna for 7 days.

•       Snehapana with Shatpala ghrita for (3-7 days)(until samyak snigdha lakshana obtained) an average of 5 days.

•       Sarvanga abhbyanga with Saindhavadi taila and swedana with dashamoola kwatha for 3 days.

•       Virechana karma with Trivrit avaleha,Triphala kwatha and Gandharvahastadi eranda taila  for 1 day.

•       Samsarjana krama with peya, vilepi etc. for (3-7 days) an average of 5days as per shuddhi.

•       Yoga basti for 8 days :

Anuvasan vasti with Br.Saindhavadi taila and Shatapushpa for 5 days (on 1,3,5,7,8th day)

Niruha basti with Guda, Saindhav Lavana, Amlika, Shatpushpa kalka and Gomutra arka for 3 days (on 2,4,6th day)

•       So total no of days with an average of( Rukshana , Snehana ,Virechana and

Samsarjana krama and Yoga basti is 30 days) + (oral medication -30days) +( follow up after completion of shamana aushadhi– 30days ) = 90days

 TOTAL STUDY DURATION-90 DAYS

 

ASSESSMENT PARAMETERS 12

1.     BASDAI (Bath Ankylosing Spondylitis Disease Activity Score)

2.     BASFI (Bath Ankylosing Spondylitis Functional Index) 

3.     BASMI (Bath Ankylosing Spondylitis Metrology Index)

4.     Visual Analogue Score

5.     C-Reactive Protein (q-CRP)

6.     ESR

7.     Serum Interleukin 17- As per feasibility.

 


 
Close